OAR@UM Collection:
/library/oar/handle/123456789/32096
2025-12-27T20:00:45ZThe role of the mesolimbic dopamine system in interferon-α mediated anhedonia
/library/oar/handle/123456789/32266
Title: The role of the mesolimbic dopamine system in interferon-α mediated anhedonia
Abstract: SAMMUT, S. The role of the mesolimbic dopamine system in Interferon-a
mediated anhedonia
Changes in sucrose intake were used as a measure of anhedonia. Non-drug
manipulations confirmed that the differences observed in the sucrose concentration-intake
curve between the single-bottle and three-bottle were not due to aversion or
satiety but more likely attributable to an effort to regulate reward to an optimal level.
In the single-bottle test increasing hours of deprivation prior to sucrose tests, nonspecifically
altered sucrose intake, while increasing the response-force requirement to
access the sucrose solutions decreased the consumption of the 1 % solution and
increased the intake of the 32% solution, effectively shifting the bell-shaped response reward
curve to the right. This effect was attributed to the motivational drive
associated with the perceived reward value of the sucrose solution on offer.
Sucrose intake is subject to modulation by several neurotransmitters including
DAergic as evident by the effects of raclopride (RAC), a D2/D3/D4 receptor
antagonist, glutamatergic (MK-801, non-competitive NMDA receptor antagonist) and
GABAergic (muscimol and b acI of en , GABAA and GABAB receptor agonists
respectively) systems which showed a similar intake pattern to those of increased
response force requirement (i.e. decreased consumption at the 1 % sucrose solution
and increased consumption at the 32% solution). Administration of chlordiazepoxide
(CDP, a benzodiazepine anxiolytic) however, produced a non-specific increase at all
concentrations of sucrose. These results indicate a close interaction between DA,
GABA and glutamate in sucrose reward and anhedonia.
rHIFN-α is a cytokine used in the treatment of various viral illnesses. A major
limiting factor in the therapy is depression. Acute administration of rHIFN-α
decreased sucrose intake in a three-bottle test at all concentrations of sucrose,
although the effect was greater at 1 % solution. Chronic administration of rHIFN-α
decreased sucrose intake at the 1 % and increased that at the 32%. The increase in
consumption of the 32% solution was reversed by the chronic administration of a
tricyclic and selective serotonin reuptake inhibitor antidepressant. rHIFN-α however
failed to alter locomotor activity or amphetamine (AMP)-induced sensitisation.
Using in vitro voltammetry in brain slices, it was shown that peripheral pretreatment
with AMP led to increased levels of DA in the nucleus accumbens (NAcb)
core relative to the rats that had been treated with vehicle. rHlFN- α, reduced evoked
DA release in the NAcb core at all frequencies of stimulation. The administration of
anti-human lFN-cx, antibody (mHlFNAb) reversed the decrease in sucrose intake at the
32% solution produced by the acute administration of rHlFN-cx,. This strongly
suggests that the behavioural effects produced by lFN- α, may be related to these
central dopaminergic changes. These findings are discussed in relation to a
behavioural model for rHINF-α,-induced depression and relative to furthering our
understanding into the possible mechanisms through which rHIFN-α, may produce
depression in patients and possible therapeutic strategies to alleviate such.
Description: PH.D.2001-01-01T00:00:00Z